The role of amyloidogenic protein oligomerization in neurodegenerative disease (Q38093118)

28 August 2017

The role of amyloidogenic protein oligomerization in neurodegenerative disease (English)

1 reference

28 August 2017

1 reference

Gregor P Lotz

1

1 reference

PubMed ID

23529761

28 August 2017

Justin Legleiter

series ordinal

2

1 reference

28 August 2017

27 March 2013

1 reference

Journal of Molecular Medicine

28 August 2017

1 reference

28 August 2017

91

1 reference

28 August 2017

653-664

1 reference

28 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s00109-013-1025-1

28 August 2017

0 references

cites work

Protein misfolding, functional amyloid, and human disease

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Familial conformational diseases and dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Glimpses of the molecular mechanisms of beta2-microglobulin fibril formation in vitro: aggregation on a complex energy landscape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

In situ atomic force microscopy study of Alzheimer's beta-amyloid peptide on different substrates: new insights into mechanism of beta-sheet formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Amyloid oligomers: formation and toxicity of Abeta oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Amyloid Fibrils of Mammalian Prion Protein Are Highly Toxic to Cultured Cells and Primary Neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Some morphometric aspects of the brain in senile dementia of the alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Contribution of somal Lewy bodies to neuronal death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

A cellular model that recapitulates major pathogenic steps of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Serine phosphorylation suppresses huntingtin amyloid accumulation by altering protein aggregation properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

A specific amyloid-beta protein assembly in the brain impairs memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Identifying polyglutamine protein species in situ that best predict neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

CAG repeat number governs the development rate of pathology in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

In vivo demonstration that alpha-synuclein oligomers are toxic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Polymorphism in the intermediates and products of amyloid assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Abeta(1-40) forms five distinct amyloid structures whose beta-sheet contents and fibril stabilities are correlated

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

The protofilament structure of insulin amyloid fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Insulin forms amyloid in a strain-dependent manner: an FT-IR spectroscopic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Ultrastructural organization of amyloid fibrils by atomic force microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Structural classification of toxic amyloid oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's β-amyloid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Direct characterization of amyloidogenic oligomers by single-molecule fluorescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Slow amyloid nucleation via α-helix-rich oligomeric intermediates in short polyglutamine-containing huntingtin fragments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

A causative link between the structure of aberrant protein oligomers and their toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Identification of two biologically distinct strains of transmissible mink encephalopathy in hamsters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Effects of agent strain and host genotype on PrP accumulation in the brain of sheep naturally and experimentally affected with scrapie.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

The physical basis of how prion conformations determine strain phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Purified and synthetic Alzheimer's amyloid beta (Aβ) prions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Transmission and spreading of tauopathy in transgenic mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Prion-like acceleration of a synucleinopathy in a transgenic mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Alzheimer's pathogenesis: is there neuron-to-neuron propagation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Focality of upper and lower motor neuron degeneration at the clinical onset of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Countering amyloid polymorphism and drug resistance with minimal drug cocktails

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

A synergistic small-molecule combination directly eradicates diverse prion strain structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

ANS binding reveals common features of cytotoxic amyloid species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Adapting proteostasis for disease intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Impairment of the ubiquitin-proteasome system by protein aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Progressive disruption of cellular protein folding in models of polyglutamine diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Neurotoxic protein oligomerisation associated with polyglutamine diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Alpha-synuclein locus duplication as a cause of familial Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

alpha-Synuclein locus triplication causes Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Aberrant protein interactions in amyloid disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

The shock of aging: molecular chaperones and the heat shock response in longevity and aging--a mini-review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Protein homeostasis and aging: The importance of exquisite quality control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Modulation of neurodegeneration by molecular chaperones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Impaired heat shock response in cells expressing full-length polyglutamine-expanded huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Global changes to the ubiquitin system in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on Aβ induced membrane disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Generic cell dysfunction in neurodegenerative disorders: role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Point mutations in Aβ induce polymorphic aggregates at liquid/solid interfaces

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Formation of amyloid fibers triggered by phosphatidylserine-containing membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Neural membrane phospholipids in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

21 January 2018

Amyloid peptide channels

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Amyloid ion channels: a common structural link for protein-misfolding disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Oligonucleotide therapeutic approaches for Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Therapeutic approaches to protein-misfolding diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Inhibition of protein misfolding and aggregation by small rationally-designed peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Hsp90 molecular chaperone inhibitors: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Hope in Alzheimer's fight emerges from unexpected places.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Tafamidis for transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Protein aggregates in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Tau in Alzheimer disease and related tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Acetylation of tau inhibits its degradation and contributes to tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Chaperone networks: tipping the balance in protein folding diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

The diverse members of the mammalian HSP70 machine show distinct chaperone-like activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

DnaJA1 antagonizes constitutive Hsp70-mediated stabilization of tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Disease-modifying treatments for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Alzheimer's disease market: hope deferred

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1025-1

Formation of toxic fibrils of Alzheimer's amyloid beta-protein-(1-40) by monosialoganglioside GM1, a neuronal membrane component

21 January 2018

1 reference

12 December 2020

Morphological changes in the human cerebral cortex in dementia

1 reference

12 December 2020

Architecture and polymorphism of fibrillar supramolecular assemblies produced by in vitro aggregation of human calcitonin

1 reference

12 December 2020

Polymorphic Fibrillar Assembly of Human Amylin

1 reference

12 December 2020

The Human Islet Amyloid Polypeptide Forms Transient Membrane-Active Prefibrillar Assemblies†

1 reference

12 December 2020

Huntington aggregates may not predict neuronal death in Huntington's disease

1 reference

12 December 2020

Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.

1 reference

12 December 2020

Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development

1 reference

12 December 2020

Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice.

1 reference

12 December 2020

Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy.

1 reference

12 December 2020

Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state

1 reference

12 December 2020

10.1007/S00109-013-1025-1

Identifiers

DOI

1 reference

PubMed ID

23529761

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23529761